SynthesisThe Cochrane database of systematic reviews2000
Aspirin for vascular dementia.
Synthesis in The Cochrane database of systematic reviews, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Association between aspirin use and risk of dementia: a systematic review and meta-analysis.European geriatric medicine · 2024Pooled it
- Effects of the use of autobiographical photographs on emotional induction in older adults: a systematic review.Psychological research · 2023Pooled it
- Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.The Cochrane database of systematic reviews · 2020Pooled it
- Low-Dose Aspirin Use and Cognitive Function in Older Age: A Systematic Review and Meta-analysis.Journal of the American Geriatrics Society · 2017Pooled it
- Acupuncture for vascular dementia.The Cochrane database of systematic reviews · 2007Pooled it
- Trial
- "The association of cardiometabolic diseases and related medications with cognitive performance: a cross-sectional observational study from Central Poland".BMC geriatrics · 2025Observational
- Aspirin and Risk of Dementia in Patients with Late-Onset Depression: A Population-Based Cohort Study.BioMed research international · 2020Article
- Chronic Heart Failure Care Planning: Considerations in Older Patients.Cardiac failure review · 2017Article
- Cognitive Impairment and Age-Related Vision Disorders: Their Possible Relationship and the Evaluation of the Use of Aspirin and Statins in a 65 Years-and-Over Sardinian Population.Frontiers in aging neuroscience · 2014Article
- Vascular cognitive change: perspective from neurology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2007Article
- Neuropsychiatric consequences of cardiovascular medications.Dialogues in clinical neuroscience · 2007Review
- Treatment of vascular dementia: evidence from epidemiologic studies.Current treatment options in cardiovascular medicine · 2005Article
- Does aspirin protect against Alzheimer's dementia? A study in a Swedish population-based sample aged > or =80 years.European journal of clinical pharmacology · 2003Article
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor patients with a diagnosis of vascular dementia there is evidence that aspirin is widely prescribed - in one study, completed by geriatricians and psychiatrists in the UK, 80% of patients with cognitive impairment (with vascular risk factors) were prescribed aspirin. However, a number of queries remain unanswered: Is there convincing evidence that aspirin benefits patients with vascular dementia? Does aspirin affect cognition or improve prognosis? In addition, does the risk of cerebral or gastric haemorrhage outweigh any benefit?
objectivesTo assess the evidence of effectiveness of the use of aspirin for vascular dementia. SEARCH STRATEGY: Computerized databases were searched independently by two reviewers. In addition, relevant websites were searched and some journals were handsearched. Specialists in the field were approached for unpublished material and any publications found were searched for additional references. The most recent search for trials was carried out in February 2000. SELECTION CRITERIA: All randomized controlled trials investigating the effect of aspirin for vascular dementia are included. Inclusion/exclusion of studies comprised systematic assessment of the quality of study design and the risk of bias. DATA COLLECTION AND ANALYSIS: Data were extracted independently by both reviewers, using a previously tested data extraction form and, where required, authors were contacted for data not provided in the papers. The aim is to evaluate data recorded via tools assessing cognitive and behavioural changes along with mortality, morbidity and institutionalization data. MAIN
resultsNo trials are eligible for inclusion in this review. REVIEWER'S
conclusionsThere is no evidence that aspirin is effective in treating patients with a diagnosis of vascular dementia. Further research is needed to assess the effect of aspirin on cognition, and on other outcomes such as behaviour, and quality of life. At present there is no evidence relating to other queries about the use of aspirin for dementia (these are described in the Background section of this review). The most recent search for references to relevant research was carried out in February 2000, but no new evidence was found.
Indexed as
Identifiers
11034710What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.